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ABSTRACT
Objectives: The aim of the study was to assess the prescribing pattern of antidiabetic drugs in Type 2 diabetes outpatients visiting to Diabetes Centre, 
Chennai.
Methods: A prospective study was carried out by evaluating 115 prescriptions of antidiabetic drugs over the period of 4 months to assess the 
prescribing pattern of antidiabetic drugs and also drugs used for other complications of Type 2 DM.
Results: Totally, 115 patients were evaluated, 58 were of male and 57 were of female. An average number of drugs per encounter were found to be 
4.47. An average number of antidiabetic drugs were found to be 2.56. In this study, the most commonly prescribed oral hypoglycemic drug class as 
single-drug regimen was that of alpha-glucosidase inhibitors (16.326%), dipeptidyl peptidase-4 (DPP-4) inhibitors (14.62%), biquanides (12.9%), 
thiazolidine diones (9.8%), sulfonyl urea (7.82%) and meglitinides (2.38%), and in multi drug regimen metformin + alpha-glucosidase inhibitors 
(11.56%) were commonly prescribed.
Conclusion: Most commonly used drug was alpha-glucosidase inhibitors, followed by DPP-4 inhibitors and biguanides. All the patients received 
combination therapy to achieve the glycemic control.
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INTRODUCTION
Diabetes mellitus (DM) is a chronic metabolic disorder characterized 
by disturbances in the metabolism of carbohydrate, fat, and protein 
due to varying degrees of insulin secretion either hyposecretion or 
insulin insensitivity, in which there are high blood sugar levels over a 
prolonged period that requires lifelong medical treatment and ongoing 
patient self-management and support to prevent acute complications 
and to reduce the risk of morbidity and mortality [1,2]. In India, 2000, 
the prevalence of diabetes was estimated to be 31.7 million, followed 
by China (20.8 million) and in the United States (17.7%). It is predicted 
in India that the diabetes population may rise up to 79.4 million 
individuals by 2030 [3,4]. Prevention and treatment involves a healthy 
diet, physical exercise, avoid tobacco, and being a normal body weight. 
Drug utilization studies are important to optimize the drug use, and it 
serves as an important tool those are in need of receiving medication 
and cost-effective treatment. The main aim of the diabetes management 
study is to prevent the development of micovascular complications and 
reduction in patient financial cost.
METHODS
This was a prospective study carried out in outpatients of the Aruna 
Diabetes Centre, Chennai. Permission from Institutional Human Ethics 
Committee (Ref: IEC/PHD/2015/2016/01), Vels University, Chennai, 
was obtained to conduct the study at Aruna Diabetes Centre,Chennai. 
The sample size for this study was 115 patients with the duration of 
4 months (July 2016 to October 2016). Type 2 DM patients of 18 years 
and above receiving antidiabetic drugs of new and existing cases were 
selected for participation after fulfilling the inclusion and exclusion 
criteria. We excluded Type 1 diabetes patients, pediatric and pregnant 
women, and patients not willing to participate in this study. After 
obtaining the informed consent, sociodemographic data along with the 
details of antidiabetic therapy, duration of treatment was recorded.
Type 2 diabetes patients receiving only one active ingredient defined as 
monotherapy, whereas patients receiving medication with more than 
one active ingredient were defined as combination therapy.
RESULTS
The prospective study involving 115 prescriptions of patients with 
Type 2 DM is visiting to Aruna Diabetes Centre, Chennai. Patients 
were divided into four groups on the basis of ages: Less than 
40 years, 41-60 years, above 61-80 years, and above 80 years. The 
demographic characteristics of the patients were studied: Gender, 
age, duration of diabetes, and comorbidities. Out of 115 prescriptions 
analyzed, male were 58 (50.43%), female were 57 (49.56%), and the 
mean age of the sample was 54.73±12.43 years (Table 1).
Out of 115 prescriptions, the total number of drugs prescribed to be 515. 
In which, 57.09% were antidiabetic drugs, whereas 42.91% prescribed 
for diabetic complications and for hypertension, hypercoagulation, and 
peripheral neuropathy and thyroid disorders. During this study, Type 
2 diabetes patients receiving a number of antidiabetic drugs vary from 
one of eight drugs. An average number of drugs received per patient 
were found to be 4.47. The average number of antidiabetic drugs 
received per individual was found to be 2.56. The study found a higher 
incidence of diabetes among adult patients, with a high incidence in 
the age group of 41-60 years (58.56% of the total) followed by the 
age group above (28.7% of the total) (Table 2). The average duration 
of diabetes was 11.44±7.11 (mean±standard deviation [SD]) (Table 3).
In this study, in single-drug regimen and multidrug regimen the most 
commonly prescribed oral hypoglycemic drug class was that of alpha-
glucosidase inhibitors (18.3%) DPP-4 inhibitors (14.62%), biquanides 
(12.925%), thiazolidine danes (9.8%), sulfonyl urea (7.82%), 
meglitinides (2.38%), sodium glucose transport, or inhibitors (1.02%) 
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were prescribed. In multi-drug regimen, biquanides + alpha-glucosidase 
inhibitors (11.6%) biquanides +sulfonyl urea (10.5%), biquanides + 
DPP-4 inhibitors (6.46%), biquanides + meglitinides (1.7%), sulfonyl 
urea+ alpha-glucosidase inhibitors (0.68%), sulfonylurea+thiazolidine 
dione (0.34%) were prescribed. In three drug combination, 
biquanides + sulfonyl urea + alpha-glucosidase inhibitors (0.34%) and 
biguanides + thiazolidine diones+ alpha-glucosidase inhibitors (0.34%) 
were prescribed. Insulin injection was prescribed to 2.52% of the total 
drug population (Tables 4 and 5).
Duration of diabetes plays an important role in patients suffering from 
a long time. A firm blood glucose control results in lesser incidence 
of complications such as nephropathy were related to the duration 
of diabetes. In this study, majority of patients fall under the category 
of 11-15 years (26.08%), 6-10 years (25.17%) followed by 1-5 years 
(20%), and new case (4.3%) (Table 3). In our study, minimum of 2 drugs 
prescribed to 6.07% patients, majority of prescriptions with 4 drugs 
(27.83%) and 5 drugs (25.22%) were prescribed and maximum of 
8 drugs prescribed to 3.48% of prescriptions (Table 6). Cardio vascular 
complications were reported in 29.56% of patients and they were 
treated with various lipid-lowering drugs such as rosuvastatin (2.92% 
of total drugs), atorvastatin (1.28% of total drugs). Aspirin (1.28% 
of total drugs), clopidogrel (1%), and finofibrate (1 in number) were 
also prescribed to prevent heart-related problems. Out of 115 patients, 
78 patients (63.83%) had a family history of diabetes.
In this study, hypertension (42.6%) was the common comorbidity 
observed. Of the total study population, 53% of patients were having 
coexisting illness, in which hypertension was the predominant. 
Hypertension was frequently associated with increased stiffness of 
large arteries, which often precedes macrovascular events.
Microvascular complications were detected in patients with neuropathy 
15 (13%), they were treated with alpha lipoic acid, benfotiamine, 
mecobalamin, folic acid, pyridoxine combination of drugs, gabapentin, 
pregabalin, and epalrestat. Nephropathy detected in 31 patients 
(26.95%), they were treated with angiotensin II receptor blockers such 
as olmesartan (5 in numbers), losartan (5 in numbers), telmisartan 
(10 in numbers) were given to the patient and (3 numbers), ramipril (1 
in number). Retinopathy detected in 19 patients (16.52%) identified by 
fundoscopy 3 nethra.
In the present study, voglibose was the most commonly prescribed 
monotherapy, second commonly prescribed drug was metformin, 
pioglitazone and vildagliptin. Metformin was the only one antidiabetic 
drug prescribed commonly in both single-drug regimen and multidrug 
regimen.
DISCUSSION
In this drug utilization study, an attempt has been made to describe the 
current prescribing pattern of anti diabetic drugs of Type 2 diabetes 
patients at the general private diabetes center, Chennai, was prescribed 
almost equally to men (50.43%) and women (49.56%). The prevalence 
of Type 2 DM was maximum in the age group of 41-60 years (58.56%). 
Similar studies were carried out in India in Indore city where the 
maximum patients are in the age group of 51-60 and 41-50 years [5]. 
The mean age of the patient was 52.84±1.0. The average number 
of anti-diabetic drugs per prescription was 2.6. In our study, 67% of 
drugs prescribed as single-drug regimen and 33% as single drug 
regimen and multi-drug regimen. In other studies conducted in India 
were performed in five private clinics of a locality of Hyderabad, 74.5% 
prescribed as monotherapy, and 24.5% as combination therapy [6].
The average duration of diabetes was 11.44±7.11 (mean±SD). The 
duration of diabetes plays an important role in the management of 
diabetes. Patients who have <5 years could generally be managed with 
monotherapy while the patients having more than 5 years are required 
combination therapy. In our present study, only 24.3% of patients were 
present <5 years and 25.17% had the duration of more than 5-10 years, 
40.38% above 10 years, and the majority of the patients received 4 and 
5 drugs in our study (Table 6). Another study carried out in India in the 
year 2015-16 by Haghighatpanah et al., patients <5 years, 5-10 years and 
>10 years of diabetes duration were 21.9%, 24.4%, and 53.7%, respectively. 
The above study indicates that the majority of the patients (79%) had 1-2 
antidiabetic drugs and 20.7% prescribed with 3-4 antidiabetic drug [7]. In 
our study, hypertension (42.6%) was the common comorbidity observed. 
A similar study was conducted by Brian and Charles, hypertension 
(42.2%) was the highest common comorbidity observed in Type 2 DM in 
Nigeria, and the average number of drugs prescribed were 4±1.6 [8].
In this present study, highly prescribed single-drug regimen was alpha-
glucosidase inhibitors 16.326% of total drug prescribed. Voglibose 
was predominantly prescribed in this category. Treatment with alpha-
Table 1: Gender categorization of the patients
Gender Number of patients n=115 (%)
Male 58 (50.43)
Female 57 (49.56)
Datas are expressed as number and percentage
Table 2: Demographic data of the patients





Datas are expressed as number and percentage
Table 3: Distribution of the diabetic patients according to 
duration of years
Duration of years Number of patients n=115 (%)





Above 20 13 (11.3)
Datas are expressed as number and percentage
Table 4: Prescribing pattern of oral hypoglycemic drug as single 
drug regimen based on various classes of drugs
Name of the 
drugs
Number of times 
prescribed




















Datas are expressed as number and percentage
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glucosidase inhibitor delays carbohydrate absorption after meals, 
significantly reduced post-meal hyperglycemia, along with the risk 
of myocardial infarction and other cardiovascular events with Type 2 
diabetes [9] and impaired glucose tolerance [10].
The study conducted by Talaviya et al. alpha-glucosidase inhibitors 
prescribed as an add-on therapy with metformin and sulfonylureas 
in uncontrolled obese and overweight patients of Type 2 DM provide 
desired glycemic control, improvement in lipid profile, and decreases in 
body weight [11]. Metformin + alpha-glucosidase inhibitors (11.56%) 
prescribed highest in our study.
Next, to alpha-glucosidase inhibitors, 14.62% of patients received 
dipeptidyl peptidase-4 (DPP-4) inhibitors. The study documented 
higher number of DPP-4 inhibitors such as vildagliptin (9.52%) 
prescribed. DPP-4 inhibitors use has greatly increased with uncontrolled 
overweight/obese; this result is in agreement with other reports 
conducted worldwide [12-14]. Another study carried out by Tolba et al., 
vildagliptin as an add-on therapy to gliclazide was not associated with 
the cardiovascular risks and showed the significant reduction in the 
hemoglobin A1c and fasting blood sugar [15].
In our study, metformin 12.925% were prescribed as a single drug, and 
as in combination therapy, 31.96% were prescribed, almost in all the 
prescription metformin was present. According to the statement of the 
American Diabetes Association and European Association for the Study 
of Diabetes guidelines also endorses metformin is the first-line drug 
for Type 2 diabetes patients and has the lowest risk of hypoglycemia, it 
does not cause weight gain and weight loss, has the beneficial effect of 
lowering the lipid levels and available at a low cost [16,17]. The study 
conducted by different groups reported that an increase in the use of 
metformin and decrease in the use of sulfonylureas [18-21]. The add-
on therapy of sulfonylurea to metformin is the common procedure after 
the metformin fails to control glycemic levels, sulfonylureas have been 
associated with hypoglycemia, sometimes need of hospitalizations, 
particularly in elderly patients [22].
CONCLUSION
Among all the anti-diabetic drugs, class of alpha-glucosidase inhibitors, 
DPP-4, and metformin combinations played an important role in 
the maintenance of glycemic levels in Type 2 diabetes patients. We 
could see the decrease in the use of sulfonyl ureas; it causes weight 
gain and increases in the risk of cardiovascular complications. All 
the prescriptions, receiving a single-drug regimen as well as multiple 
drug regimen. All the prescriptions were dispensed with minimum 2 
and maximum of 8 drugs. The number of drugs prescribed to patients 
increased due to their complications and existing comorbidities. 
Further investigation is needed to study the patient compliance and 
educations regarding diabetes, and lifestyle modification is also 
important to achieve the optimal glycemic control.
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